Tert-butyl 4-[2-[[5-[4-[5-[[2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]acetyl]amino]-1,3,4-thiadiazol-2-yl]butyl]-1,3,4-thiadiazol-2-yl]amino]-2-oxoethyl]piperidine-1-carboxylate | 1439390-48-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Tert-butyl 4-[2-[[5-[4-[5-[[2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]acetyl]amino]-1,3,4-thiadiazol-2-yl]butyl]-1,3,4-thiadiazol-2-yl]amino]-2-oxoethyl]piperidine-1-carboxylate
• CAS: 1439390-48-3
• 化学式: C₃₂H₅₀N₈O₆S₂
• 分子量: 706.931
• InChiKey: XFUJMDUUSOBRMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  48
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  225
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• HETEROCYCLIC INHIBITORS OF GLUTAMINASE
  申请人：Calithera Biosciences Inc.

  公开号：US20130157998A1

  公开（公告）日：2013-06-20

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.

  本发明涉及新型杂环化合物及其制药制剂。本发明还涉及使用所述新型杂环化合物治疗的方法。
• TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE
  申请人：Calithera Biosciences, Inc.

  公开号：US20150004134A1

  公开（公告）日：2015-01-01

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

  本发明涉及新型杂环化合物及其制药制剂。本发明还涉及使用所述新型杂环化合物治疗或预防癌症的方法。
• Treatment of lung cancer with inhibitors of glutaminase
  申请人：Calithera Biosciences, Inc.

  公开号：US10441587B2

  公开（公告）日：2019-10-15

  The invention relates to methods of treating lung cancer using glutaminase inhibitors. In particular, results demonstrate that lung cancers characterized by an EGFR or KRAS mutation are treated by glutaminase inhibitors.

  本发明涉及使用谷氨酰胺酶抑制剂治疗肺癌的方法。特别是，研究结果表明，以表皮生长因子受体（EGFR）或KRAS突变为特征的肺癌可通过谷氨酰胺酶抑制剂进行治疗。
• TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE
  申请人：Liang Yu

  公开号：US20180055825A1

  公开（公告）日：2018-03-01

  The invention relates to method of treating a disease or disorder (e.g., such as cancer) in a subject, comprising administering to the subject heterocyclic compounds and pharmaceutical preparations described herein, if the subject is determined to possess at least one G allele at single nucleotide polymorphism (SNP) rs6983267.
• Heterocyclic Inhibitors of Glutaminase
  申请人：Calithera Biosciences, Inc.

  公开号：US20200165238A1

  公开（公告）日：2020-05-28

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.